Boone Capital Management LLC
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Boone Capital Management LLC reported 16 stock positions worth $427.5 million. Its top holding was Teleflex (TFX) at 11.5% of the portfolio, followed by Mirum Pharmaceuticals (MIRM, 11.4%) and Cigna (CI, 10.3%). Compared with Q1 2026, it opened 7 new positions, sold out of 4, added to 8 and reduced 1. The biggest buy was a new position in Vestis (VSTS) and the biggest sale an exit from Medtronic (MDT).
- Most Recent 13F
- Q2 2026
- Location
- ATLANTA, GA
- CIK
- 0001882053
- Portfolio Value
- $427.5M (Q2 2026)
- SEC Filing
- 0001214659-26-010362 ↗ filed Aug 14, 2026
Holdings Value
Holdings 16 stocks · $427.5M
| TFX Teleflex Inc. | 11.49% | 387,388 | $49.1M | Add +39.0% |
| MIRM Mirum Pharmaceuticals Inc. | 11.38% | 415,641 | $48.7M | Reduce -1.3% |
| CI The Cigna Group | 10.27% | 159,290 | $43.9M | Add +15.8% |
| IONS Ionis Pharmaceuticals Inc. | 9.64% | 519,977 | $41.2M | Add +3.9% |
| UNH Unitedhealth Group Inc. | 8.62% | 88,687 | $36.9M | Add +11.9% |
| BMRN Biomarin Pharmaceutical Inc. | 7.81% | 583,219 | $33.4M | Add +6.5% |
| GRDN Guardian Phrmcy Services-A | 6.97% | 711,939 | $29.8M | Add +12.8% |
| VSTS Vestis Corp. | 6.45% | 1,900,140 | $27.6M | New |
| BBIO Bridgebio Pharma Inc. | 5.92% | 339,720 | $25.3M | Add +48.5% |
| PNTG The Pennant Group Inc. | 4.46% | 515,818 | $19.1M | New |
| GLUE Monte Rosa Therapeutics Inc. | 3.48% | 615,287 | $14.9M | New |
| KOD Kodiak Sciences Inc. | 3.44% | 378,010 | $14.7M | Add +34.4% |
| TNGX Tango Therapeutics Inc. | 3.33% | 455,605 | $14.2M | New |
| KYMR Kymera Therapeutics Inc. | 3.04% | 113,173 | $13.0M | New |
| CGEM Cullinan Therapeutics Inc. | 3.00% | 704,442 | $12.8M | New |
| ANL Adlai Nortye Group Ltd. | 0.69% | 258,390 | $3.0M | New |
Portfolio Sells Q1 2026 → Q2 2026
Portfolio Buys Q1 2026 → Q2 2026
| VSTS Vestis Corp. | New | 6.45% | +6.45 |
| PNTG The Pennant Group Inc. | New | 4.46% | +4.46 |
| GLUE Monte Rosa Therapeutics Inc. | New | 3.48% | +3.48 |
| TNGX Tango Therapeutics Inc. | New | 3.33% | +3.33 |
| KYMR Kymera Therapeutics Inc. | New | 3.04% | +3.04 |
| CGEM Cullinan Therapeutics Inc. | New | 3.00% | +3.00 |
| UNH Unitedhealth Group Inc. | Add +11.9% | 8.62% | +2.05 |
| TFX Teleflex Inc. | Add +39.0% | 11.49% | +1.27 |
| BBIO Bridgebio Pharma Inc. | Add +48.5% | 5.92% | +0.71 |
| ANL Adlai Nortye Group Ltd. | New | 0.69% | +0.69 |
| KOD Kodiak Sciences Inc. | Add +34.4% | 3.44% | +0.16 |
| GRDN Guardian Phrmcy Services-A | Add +12.8% | 6.97% | −0.31 |
| CI The Cigna Group | Add +15.8% | 10.27% | −0.97 |
| BMRN Biomarin Pharmaceutical Inc. | Add +6.5% | 7.81% | −1.68 |
| IONS Ionis Pharmaceuticals Inc. | Add +3.9% | 9.64% | −1.87 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 16 | $427.5M | TFX, MIRM, CI, IONS, UNH |
| Q1 2026 | 13 | $326.4M | MIRM, IONS, CI, MDT, TFX |
| Q4 2025 | 15 | $318.6M | MDT, MIRM, IONS, CI, BMRN |
| Q3 2025 | 16 | $305.0M | MDT, MIRM, IONS, CI, BBIO |
| Q2 2025 | 11 | $233.2M | MDT, MIRM, BMRN, AVTR, UNM |
| Q1 2025 | 12 | $293.8M | UNM, MDT, MIRM, GMED, CI |
| Q4 2024 | 13 | $296.5M | UNM, GMED, PRGO, MIRM, MOH |
| Q3 2024 | 17 | $385.8M | UNM, GMED, CI, MOH, CHE |
| Q2 2024 | 19 | $383.4M | UNM, GMED, CI, MOH, DHR |
| Q1 2024 | 21 | $494.4M | UNM, CI, MOH, ENOV, BAX |